Cell line · CVCL_0397
Papers54
1 to 20 of 54
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Visceral and subcutaneous adipose stem cells modulate colorectal cancer cell progression: direct and indirect contact distinctly accelerate tumor aggressiveness. | Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BMP antagonist CHRDL2 enhances the cancer stem-cell phenotype and increases chemotherapy resistance in colorectal cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The solute carrier superfamily interactome. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic mapping of the human solute carrier superfamily. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39713466 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39605519 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0397/papers